Groundbreaking HIV cure study in South Africa shows the safety and potential efficacy of a novel therapeutic regimen in women ...

TaiMed Biologics (4147 TWO), an innovation-driven biotech company, has Phase 2a clinical study evaluating TMB-365/TMB-380 ...

Hepatitis C virus (HCV) infection remains a major global health burden, affecting millions worldwide and contributing significantly to hepatocellular ...

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

Based upon a successful engagement with the US Food and Drug Administration (FDA) at the End-of-Phase 2 meeting in January ...

Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...

Consider liver biopsy if HBV DNA > 20,000 IU/ml, ALT ≤2 x ULN and age > 40 years or family history of HCC Consider therapy if histologic disease and ALT ≤2 x ULN HBV DNA ≥20,000 IU/ml and ...

Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...

Between 1995 and 2023, diagnoses of hepatitis C infection increased among HIV-positive men who have sex with men with no history of injection drug use, particularly during the era of highly active ...